Titan Medical Expands Advisory Role for Dr. Arnold Advincula to Include Clinical Education and Hospital Economics
August 02 2018 - 7:15AM
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD)
(NASDAQ: TMDI), a medical device company focused on the
design, development and commercialization of a robotic surgical
system for application in single-port minimally invasive surgery
(“MIS”), announces an expanded advisory role for Arnold Advincula,
M.D. encompassing clinical education and hospital economics.
Dr. Advincula has served on Titan’s Surgeon
Advisory Board since 2014. In this expanded role, he will
facilitate the clinical adoption of the Company’s SPORT Surgical
System by helping Titan optimize the clinical education pathways
and the hospital economics strategy.
“We are delighted to announce this expanded
advisory role for Dr. Advincula, a world-renowned expert in robotic
gynecologic surgery. With the SPORT system, we are entering the
promising new territory of single-port robotic surgery, and under
Dr. Advincula’s expert guidance we will be well supported in
demonstrating the clinical and economic value of the SPORT system,”
said David McNally, Titan’s chief executive officer. “Dr.
Advincula has firsthand experience with the SPORT system from our
pre-clinical feasibility work. His enthusiasm for the promise of
single-port robotic surgery in gynecology and other disciplines
continues to be an inspiration to our team as we progress toward
regulatory submissions and commercialization.”
Dr. Advincula said, “I am thrilled to see the
tremendous progress Titan has made over the past 18 months under
the new management team. I have always been a firm believer in the
promise of single-port robotic surgery, and now with the right team
in place I am excited to get more involved. Clinical education is
the foundation for successful adoption of any robotic technology,
and in today’s healthcare environment it is critical to clearly
demonstrate economic value to hospital administrators. In my
expanded role at Titan, I look forward to shaping these two
fundamental pillars to demonstrate the value the SPORT Surgical
System can bring to hospital administrators, to surgeons and,
ultimately, to patients.”
About TitanTitan Medical Inc.
is focused on research and development through to the planned
commercialization of computer-assisted robotic surgical
technologies for application in minimally invasive surgery. The
Company is developing the SPORT Surgical System, a single-port
robotic surgical system. The SPORT Surgical System is comprised of
a surgeon-controlled patient cart that includes a 3D
high-definition vision system and multi-articulating instruments
for performing MIS procedures, and a surgeon workstation that
provides an advanced ergonomic interface to the patient cart and a
3D endoscopic view inside the patient’s body. Titan intends to
initially pursue focused surgical indications for the SPORT
Surgical System, which may include one or more of gynecologic,
urologic, colorectal or general abdominal procedures.
For more information, please visit the Company’s
website at www.titanmedicalinc.com.
Forward-Looking StatementsThis
news release contains “forward-looking statements” within the
meaning of applicable Canadian and U.S. securities laws. Such
statements reflect the current expectations of management of the
Company’s future growth, results of operations, performance and
business prospects and opportunities. Wherever possible, words such
as “may”, “would”, “could”, “will”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements reflect management’s current beliefs
with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions. Many
factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the Company’s Annual
Information Form dated March 31, 2018 (which may be viewed at
www.sedar.com). Should one or more of these risks or uncertainties
materialize, or should assumptions underlying the forward-looking
statements prove incorrect, actual results, performance, or
achievements may vary materially from those expressed or implied by
the forward-looking statements contained in this news release.
These factors should be considered carefully, and prospective
investors should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
the news release are based upon what management currently believes
to be reasonable assumptions, the Company cannot assure prospective
investors that actual results, performance or achievements will be
consistent with these forward-looking statements. Except as
required by law, the Company expressly disclaims any intention or
obligation to update or revise any forward-looking statements
whether as a result of new information, future events or
otherwise.
Contacts:
LHA Investor Relations Kim Sutton Golodetz(212)
838-3777kgolodetz@lhai.com orBruce Voss(310) 691-7100
bvoss@lhai.com
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Apr 2023 to Apr 2024